Creative Medical Technology Completes $1.6 Million Registered Direct Offering

PHOENIX, October 23, 2024 – Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) finalized a securities purchase agreement on October 22, 2024, with instituti

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Creative Medical Technology’s 8K filing here.

Creative Medical Technology Company Profile

(Get Free Report)

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.

Further Reading